Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio
Matinas Biopharma Holdings, Inc. (MTNB)
NASDAQ:AMEX Investor Relations:
ir.matinasbiopharma.com
Company Research
Source: GlobeNewswire
– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – – Cryptococcal meningitis is one of the most frequent and opportunistic infections in Human Immuno-Deficiency Virus (HIV) patients – – ~250,000 deaths worldwide annually despite therapy, and upwards of 15% of HIV/AIDS-related deaths – – Company plans to commence NIH-funded Phase 2 study in patients with cryptococcal meningitis in the second half of 2019 – BEDMINSTER, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the publication of efficacy results from preclinical animal models evaluating MAT2203 for the treatment of cryptococcal meningitis in the American Society for Microbiology Journal, mBio, in a manuscript titled, “Efficacy of Oral Encochleated Amphotericin B (CAmB) in a Mouse Model of Cryptococcal
Show less
Read more
Impact Snapshot
Event Time:
MTNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTNB alerts
High impacting Matinas Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MTNB
News
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Alliance Global Partners from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Alliance Global Partners from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas Biopharma Holdings, Inc. (NYSE: MTNB) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.MarketBeat
- Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionGlobeNewswire
MTNB
Sec Filings
- 11/13/24 - Form 10-Q
- 10/31/24 - Form 8-K
- 10/25/24 - Form SC
- MTNB's page on the SEC website